☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
bridgebio pharma
BridgeBio Pharma Partners with Kyowa Kirin to Develop and Commercialize Infigratinib to Treat Skeletal Dysplasias in Japan
February 7, 2024
BridgeBio Pharma Initiates P-III Study (CALIBRATE) of Encaleret for Autosomal Dominant Hypocalcemia Type 1
December 23, 2022
Bridgebio Pharma Presents 12-Month P-II Study Results of BBP-418 for Limb-Girdle Muscular Dystrophy Type 2i at WMS 2022
October 17, 2022
BridgeBio Pharma Presents P-I/II (CANaspire) Trial Results of BBP-812 for the Treatment of Canavan Disease at CNS 2022
October 14, 2022
BridgeBio Pharma Reports First Patient Dosing in P-I/II Trial for BBP-398 + Lumakras (sotorasib) to Treat Non-Small Cell Lung Canc...
October 12, 2022
BridgeBio Pharma and Sentynl Therapeutics Receive EC’s Conditional Marketing Authorization for Nulibry (fosdenopterin) to Treat Mo...
September 21, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.